Academic literature on the topic '809-873'

ABSTRACT Handroanthus impetiginosus is a tree species with ecological and economic potential. Despite that, in the Brazilian market, its wood is heavily exploited in the illegal trade. Therefore, studies on genetic diversity are necessary in order to propose strategies for conservation of this species. Thus, the aim of this study was to select Inter Simple Sequence Repeat (ISSR) primers for genetic diversity studies applied to the forest population of H. impetiginosus. For this, 30 ISSR molecular primers were tested in 30 individuals, evaluating the total number of loci, polymorphism rate and polymorphic information content, as well as marker index and resolving power. Eight primers were selected for having a better amplification pattern, which provided 62 loci. The polymorphic information content of the primers ranged from 0.34 to 0.49, while the marker index (MI) averaged 3.20, with resolving power (RP) of 2.40, Nei’s diversity (He) of 0.35 and Shannon index (I) of 0.52. The results show that the primers UBC 807, 809, 818, 824, 857, 860, 873 and 881 are efficient for quantifying the genetic diversity of H. impetiginosus. These results can contribute to supporting strategies aimed at the conservation of this species and selection of parent trees.

Abstract The University Hospital of Montpellier is the major university hospital in Languedoc-Roussillon, a region with 2.4 milions of inhabitants including 23–26% of the population having more than 65 years. This hospital includes 1015 beds and places in medicine, and 809 in surgery. Total cost of the products for transfusion concerning the hospital is 7 7606 121$. For the hematology department (56 beds, with 130–150 transplantations per year), the cost of the transfusion products represents 39.53% of the whole budget. 21.26% of the total expenditure of red blood cell (RBC) transfusion and 70.17% of the total expenditure of platelet transfusion are from this hematology department. The outpatient clinic of the department (12 beds) is the major localization for transfusing patients with MDS, representing around 20% of the activity in this part of the department. The total fee of transfusion products for this outpatient clinic is 798 739 $ with 351 464$ for RBC transfusion, representing 44%, while RBC transfusion represents 28% of the activity for the whole department, with 19.7% of increase between 2003 and 2004. The activity of hematology is linked to 2 other sites for outpatient and hospitalization in the region of Languedoc-Roussillon (including 35+10 additional beds). Similar increase of the transfusion was observed. New system of price list concerning medical activity in hospitals has been established in France, with a transfusion price fixed at 873$. By using this new accounting, transfusion appears to be slightly in deficit for an outpatient clinic in a university hospital such ours, considering the other medical activities, particularly transplantation and ambulatory chemotherapy. In addition, the number of patients with MDS is increasing in the region, according to the increase of elderness and number of treated cancers. From 01/02 to 04/05, we treat new patients having MDS, excluding AREB-t, by EPO, subcutaneously, from 12 000 to 60 000 UI per week. 85 patients entered this study. The response rate was based on an increase of hemoglobin level superior or equal to 1.5g%, or a reduction superior or equal to 30% of the transfusion consumption observed for more than 6 months. 22% of the patients reached one of these criteria, with 35% of the patients having refractory anemia (RA), sideroblastic RA or 5q- RA and only 12% of the patients having AREB. Only 5% of the patients transfused had a benefit of EPO. In some patients, we observed a dose effect of EPO between 10 000 and 40 000 UI, but at a lesser extend between 40 to 60 000 UI per week, and lasting less than 3 months. Mean duration of the effect was 1.6 year, depending the transformation risk. Benefit of EPO was not correlated with the hemoglobin level at the inclusion but to the status of MDS. Whole data concerning the indirect and direct costs will be presented for this cohort.

La prensa pedagógica profesional, como fuente y como objeto de estudio, ha sido un tema de creciente interés para los investigadores en Historia de la Educación. Muestra de ello son los numerosos repertorios analíticos publicados en distintos países, así como las investigaciones que se han llevado a cabo, ya sean de las propias publicaciones pedagógicas o de temáticas específicas. El objetivo de esta aportación consiste en realizar una revisión sistemática de la literatura producida en España sobre diferentes títulos de prensa pedagógica surgidos en el primer tercio del siglo XX (1900-1936). Para ello se han seguido las indicaciones de Sánchez-Meca (2010) y el modelo PRISMA (Moher, et al., 2009). Se han registrado 809 títulos de prensa a partir de los principales repertorios analíticos en nuestro país y, posteriormente, se ha realizado la búsqueda sistemática en las principales bases de datos científicas (Scopus, Web of Science, Dialnet y TESEO). Se han recuperado 154 investigaciones correspondientes a 55 revistas de la época estudiada, gran parte pertenecientes a los títulos de prensa pedagógica más reconocidos, de difusión nacional, como Revista de Pedagogía o el BILE, lo que demuestra que la mayoría de las publicaciones educacionales de esta época están inexploradas por la historiografía.

Abstract Background: The advent of Tyrosine Kinase Inhibitors (TKI) totally changed the outcome of patients affected by Chronic Myeloid Leukemia (CML). Most of informations about the clinical characteristics of CML patients are based on data derived from clinical trials, that often exclude patients not fitting with strict inclusion criteria. In real life may be important to know the characteristics of the entire CML patients' population and this is better reflected by registries studies including all consecutive patients. Aim: To provide a robust and updated information on clinical, hematologic characteristics and treatment response in non-selected Italian patients with CML in each phase of the disease. Methods:We retrospectively and prospectively recorder in a web-based database clinical, hematological, cytogenetic and biological informations about all new diagnosis of CML patients referred to Italian Hematology Centers of the GIMEMA Study Group from January 2012 to June 2016. Results:Our study covered 1051 patients newly diagnosed with CML and treated between January 2012 and June 2016 in 66 Italian centers. Median age at diagnosis was 59 years (range 47-71) and 60.8% were males. At diagnosis among 908 patients 899 (99%) patients were in chronic phase, 7 (0.8%) patients in accelerate phase and 2 (0.2%) in blastic crisis. Among 1051 patients, 148 (14%), 351 (33%), 318 (30.3%) were high, intermediate and low risk by Sokal with 234 (22.2%) missing; 54 (5%), 418 (40%), 342 (32.5%) high, intermediate and low risk by EURO with 237 (22.6%) missing; 55 (5%) and 797 (76%) high and low risk by EUTOS with 199 (18.9%) missing; 96 (9%), 208 (20%), 533 (51%) high, intermediate and low risk by ELTS with 214 (20.4%) missing, respectively. The median follow-up was 36 months and 36 patients died (10 CML related). At cytogenetic analysis, there were 887 available informations: 809 (77%) without additional cytogenetic aberrations (ACA), 49 (5%) with major route and 29 (2.8%) with minor route ACA respectively. BCR-ABL transcripts among 873 data available were: b2a2 in 303 (34.7%), b3a2 in 493 (56.5%), b2a2+b3a2 in 61 (7%), e1a2 in 12 (1.4%), e19a2 in 2 (0.2%) b3a2+e1a2 in 2 (0.2%) patients respectively. ECOG performance status among 801 patients was 0, 1, or ≥ 2 in 585 (73%), 181 (22.6%) and 35 (4.4%) cases respectively. According to co-morbidity and excluding CML diagnosis as parameter, among 995 cases the Charlson comorbidity index, was 0, 1, 2 or ≥3 in 771 (73.4%), 115 (11%), 60 (5.7%) and 49 (4.7%) patients respectively; among 556 patients cardiovascular, lung, metabolic and oncologic diseases were observed in 283 (24%), 108 (10.3%), 77 (7.3%) and 88 (8.4%) patients respectively. Five hundred-ten (48.5%) and 541 (51.4%) patients were treated in first-line with imatinib (IMA) and with II generation TKI (IIGen-TKI) respectively. Three hundred twenty-one (30%) cases were pretreated with hydroxyurea. Molecular responses data at 3th month were available in 728 patients and of these 102 (14.01%) obtained at least Major Molecular Response IS (MR) MR3, 29 (3.98%) MR4, 27 (3.71%) MR4.5, 13 (1.79%) MR5 and 11 (1.5%) undetectable BCR-ABL1transcript, respectively. At 6thmonth, among 731 data available, at least 292 patients (39,57%) obtained MR3, 90 (12,19%) MR4, 75(10.16%) MR4.5, 35 (4.74%) MR5 and 29 (3.97%) undetectable BCR-ABL1transcript, respectively. At 12thmonth among 709 molecular responses available, 425 patients (59.94%) achieved at least MR3, 203 (28,63%) MR4, 171 (24.12%) MR4.5, 90 (12.69%) MR5 and 78 (11%) undetectable BCR-ABL1transcript, respectively. As showed in table 1, the IIGen-TKI were able to obtain a higher, earlier and deeper molecular response at 3th, 6thand 12thmonth than IMA. Data analysis about responses at 24thmonth are ongoing. Overall survival at 5 years was 93.4% (95% IC 90.1-95.6). Conclusions:Our preliminary results of this observational epidemiologic study suggest that collection of clinical data of CML patients treated out of strictly clinical trials represent an essential tool for long/term treatment, able to observe setting strategies based on the clinical characteristics, the degree of response obtained, and the toxicity related to the therapy in overall CML population. We are planning to continue to analyze all these endpoints to estimate the response and toxicity according to ELN guidelines, and feasibility of treatment sequence in a cohort of patients treated in real-life. Disclosures Castagnetti: Pfizer: Consultancy, Honoraria; Bristol Meyers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Breccia:BMS: Honoraria; Incyte: Honoraria; Pfizer: Honoraria; Novartis: Honoraria. Pane:AMGEN: Speakers Bureau; Novartis: Research Funding, Speakers Bureau; BMS: Speakers Bureau.